These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8792779)

  • 41. Consequences of adult HIV infection for outpatient morbidity and treatment costs: a prospective study in a factory clinic in Tanzania.
    Kikumbih SN; Isingo R; Boerma JT
    Health Policy Plan; 1997 Sep; 12(3):234-9. PubMed ID: 10173404
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual diagnosis care for severe and persistent disorders. A comparison of three methods.
    Jerrell JM; Ridgely MS
    Behav Healthc Tomorrow; 1997 Jun; 6(3):26-33. PubMed ID: 10173086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The economic costs of alcohol abuse in Ontario.
    Xie X; Rehm J; Single E; Robson L; Paul J
    Pharmacol Res; 1998 Mar; 37(3):241-9. PubMed ID: 9602474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The costs of drug abuse consequences: a summary of research findings.
    French MT; Martin RF
    J Subst Abuse Treat; 1996; 13(6):453-66. PubMed ID: 9219142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Legislations and policies to expand mental health and substance abuse benefits in health insurance plans: a community guide systematic economic review.
    Jacob V; Qu S; Chattopadhyay S; Sipe TA; Knopf JA; Goetzel RZ; Finnie R; Thota AB;
    J Ment Health Policy Econ; 2015 Mar; 18(1):39-48. PubMed ID: 25862203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A critical review of accounting and economic methods for estimating the costs of addiction treatment.
    Cartwright WS
    J Subst Abuse Treat; 2008 Apr; 34(3):302-10. PubMed ID: 17614244
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV and intravenous drug use.
    Des Jarlais DC; Friedman SR
    AIDS; 1988; 2 Suppl 1():S65-9. PubMed ID: 3147682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unique Characteristics of High-Cost Users of Medical Care With Comorbid Mental Illness or Addiction in a Population-Based Cohort.
    Hensel JM; Taylor VH; Fung K; de Oliveira C; Vigod SN
    Psychosomatics; 2018; 59(2):135-143. PubMed ID: 29157683
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Guidelines and challenges for estimating the economic costs and benefits of adolescent substance abuse treatments.
    Zavala SK; French MT; Henderson CE; Alberga L; Rowe C; Liddle HA
    J Subst Abuse Treat; 2005 Oct; 29(3):191-205. PubMed ID: 16183468
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS).
    Godfrey C; Stewart D; Gossop M
    Addiction; 2004 Jun; 99(6):697-707. PubMed ID: 15139868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Benefit-cost analysis of drug abuse prevention programs: a macroscopic approach.
    Kim S; Coletti SD; Crutchfield CC; Williams C; Hepler N
    J Drug Educ; 1995; 25(2):111-27. PubMed ID: 7658292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
    Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
    Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A research agenda for economic evaluation of substance abuse services.
    French MT; Drummond M
    J Subst Abuse Treat; 2005 Sep; 29(2):125-37. PubMed ID: 16135341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study.
    Lomas J; Schmitt L; Jones S; McGeorge M; Bates E; Holland M; Cooper D; Crowther R; Ashmore M; Rojas-Rueda D; Weatherly H; Richardson G; Bojke L
    BMJ Open; 2016 Jun; 6(6):e010686. PubMed ID: 27329439
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.